行情

ACAD

ACAD

阿卡迪亚
NASDAQ

实时行情|Nasdaq Last Sale

40.17
+0.91
+2.32%
交易中 11:43 04/02 EDT
开盘
38.81
昨收
39.26
最高
40.72
最低
38.47
成交量
28.30万
成交额
--
52周最高
53.70
52周最低
21.56
市值
62.40亿
市盈率(TTM)
-25.0436
分时
5日
1月
3月
1年
5年

分析师评级

16位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ACAD价格均价为57.81,最高价位72.00,最低价为41.00。

EPS

ACAD 新闻

更多
  • Acadia Pharmaceuticals: Multiple Growth Catalysts Ahead
  • Seeking Alpha - Article · 11小时前
  • Acadia Realty Trust Withdraws FY20 Guidance
  • Benzinga · 1天前
  • HAL, APA among premarket gainers
  • Seeking Alpha - Article · 2天前
  • Mizuho sees 86% upside in Sarepta in premarket analyst action
  • Seeking Alpha - Article · 2天前

所属板块

生物技术和医学研究
+1.95%
制药与医学研究
+1.24%

热门股票

代码
价格
涨跌幅

ACAD 简况

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
展开

微牛提供ACADIA Pharmaceuticals Inc.(NASDAQ-ACAD)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ACAD股票新闻,以帮助您做出投资决策。